174 related articles for article (PubMed ID: 33811375)
1. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review.
Jaroenlapnopparat A; Chayanupatkul M; Tangkijvanich P
J Gastroenterol Hepatol; 2021 Sep; 36(9):2349-2362. PubMed ID: 33811375
[TBL] [Abstract][Full Text] [Related]
2. Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B.
Wang FD; Zhou J; Li LQ; Wang ML; Tao YC; Wang YH; Zhang DM; Chen EQ
Front Microbiol; 2022; 13():901233. PubMed ID: 35814664
[TBL] [Abstract][Full Text] [Related]
3. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
[TBL] [Abstract][Full Text] [Related]
4. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.
Carey I; Gersch J; Wang B; Moigboi C; Kuhns M; Cloherty G; Dusheiko G; Agarwal K
Hepatology; 2020 Jul; 72(1):42-57. PubMed ID: 31701544
[TBL] [Abstract][Full Text] [Related]
5. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Huang Y; Nan Y; Zheng H; Feng B
J Gastroenterol; 2021 Sep; 56(9):856-867. PubMed ID: 34292372
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
[TBL] [Abstract][Full Text] [Related]
7. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients.
Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH
Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088
[TBL] [Abstract][Full Text] [Related]
8. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
[TBL] [Abstract][Full Text] [Related]
9. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
[TBL] [Abstract][Full Text] [Related]
10. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
[TBL] [Abstract][Full Text] [Related]
11. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
[TBL] [Abstract][Full Text] [Related]
12. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation.
Tsai YN; Wu JL; Tseng CH; Chen TH; Wu YL; Chen CC; Fang YJ; Yang TH; Nguyen MH; Lin JT; Hsu YC
Clin Mol Hepatol; 2024 Jan; 30(1):98-108. PubMed ID: 38092551
[TBL] [Abstract][Full Text] [Related]
14. Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.
Xie Y; Li M; Ou X; Zheng S; Gao Y; Xu X; Yang Y; Ma A; Li J; Nan Y; Zheng H; Liu J; Wei L; Feng B
BMC Gastroenterol; 2023 Jun; 23(1):224. PubMed ID: 37386460
[TBL] [Abstract][Full Text] [Related]
15. The Role of Hepatitis B Core-Related Antigen.
Inoue T; Tanaka Y
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31075974
[TBL] [Abstract][Full Text] [Related]
16. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B.
Papatheodoridi M; Papatheodoridis G
Cells; 2020 Feb; 9(2):. PubMed ID: 32093411
[TBL] [Abstract][Full Text] [Related]
17. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
[TBL] [Abstract][Full Text] [Related]
19. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Nucleos(t)ide Analogues Discontinuation Relapse: Hepatitis B Virus RNA versus Hepatitis B Surface Antigen.
Wu S; Li T; Liu F; Yin D; Zhang L; Wang L
J Coll Physicians Surg Pak; 2024 May; 34(5):545-550. PubMed ID: 38720214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
